PLIANT THERAPEUTICS, INC. Total Liabilities and Equity
PLIANT THERAPEUTICS, INC. (PLRX) had Total Liabilities and Equity of $189.88 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-11
- 2026-06-30: Liabilities and Equity $189.88M.
- 2026-03-31: Liabilities and Equity $202.60M.
- 2025-12-31: Liabilities and Equity $225.23M.
- 2025-09-30: Liabilities and Equity $276.60M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $189.88M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $202.60M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $225.23M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $276.60M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $299.82M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $344.77M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $396.95M 10-K · filed 2026-03-11 |
| 2024-09-30 | $445.67M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $483.73M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $521.61M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $512.15M 10-K · filed 2025-03-03 |
| 2023-09-30 | $540.46M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $574.89M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $597.88M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $350.61M 10-K · filed 2024-02-27 |
| 2022-09-30 | $377.18M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $184.62M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $197.02M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $221.22M 10-K · filed 2023-03-09 |
| 2021-09-30 | $234.12M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $255.72M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $275.25M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $295.53M 10-K · filed 2022-03-01 |
| 2020-09-30 | $312.32M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $328.80M 10-Q · filed 2020-08-11 |
| 2019-12-31 | $119.06M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |